A Multicenter, Randomized, Double-blinded, Double-dummy, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment with DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients with Hypertension and Dyslipidemia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
129
Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
Sevrance Hospital
Seoul, South Korea
Change of MSSBP(Mean Sit Systolic Blood Pressure) from baseline
Time frame: 8-week
Change of LDL-C(Low Density Lipid Cholesterol) from baseline
Time frame: 8-week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.